eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase III trial of cisplatin plus paclitaxel with and without NCI-supplied bevacizumab (NSC #704865, IND #7921) versus the non-platinum doublet, topotecan plus paclitaxel, with and without NCI-supplied bevacizumab, in stage IVB, recurrent or persistent carcinoma of the cervix

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
    Topotecan hydrochloride
  5. Intervention
  6. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  7. Resource Description
    Purpose: It is not yet known whether paclitaxel is more effective when given together with cisplatin or topotecan with or without bevacizumab in treating patients with cervical cancer. This randomized phase III trial is studying the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, recurrent, or persistent cervical cancer.
  8. Contact
    Berenberg, Jeffrey
  9. PI
    Berenberg, Jeffrey
  10. Topic
    cervix carcinoma
  11. Study Population
    Females age 18 and older with measurable disease, no primary brain tumor, brain metastases, or spinal cord metastases, no previous bevacizumab, at least 6 weeks since chemotherapy with radiation therapy, at least 3 weeks since radiation therapy, and more than 4 weeks since surgery or open biopsy.
  12. Website(s)
  13. Funded by
    Gynecologic Oncology Group
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016